

# Meenhard Herlyn

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7582703/meenhard-herlyn-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

160  
papers

18,908  
citations

69  
h-index

137  
g-index

174  
ext. papers

22,360  
ext. citations

11.4  
avg, IF

6.19  
L-index

#	Paper	IF	Citations
160	Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma.. <i>Nature Communications</i> , <b>2022</b> , 13, 1381	17.4	0
159	PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery.. <i>NAR Cancer</i> , <b>2022</b> , 4, zcac014	5.2	1
158	Persister state-directed transitioning and vulnerability in melanoma. <i>Nature Communications</i> , <b>2022</b> , 13,	17.4	5
157	Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma. <i>Nature Communications</i> , <b>2021</b> , 12, 6023	17.4	1
156	Melanoma models for the next generation of therapies. <i>Cancer Cell</i> , <b>2021</b> , 39, 610-631	24.3	23
155	Evolution of delayed resistance to immunotherapy in a melanoma responder. <i>Nature Medicine</i> , <b>2021</b> , 27, 985-992	50.5	11
154	ARID2 Deficiency Correlates with the Response to Immune Checkpoint Blockade in Melanoma. <i>Journal of Investigative Dermatology</i> , <b>2021</b> , 141, 1564-1572.e4	4.3	5
153	IspH inhibitors kill Gram-negative bacteria and mobilize immune clearance. <i>Nature</i> , <b>2021</b> , 589, 597-602	50.4	17
152	Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. <i>Nature Communications</i> , <b>2021</b> , 12, 346	17.4	34
151	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. <i>Nature Genetics</i> , <b>2021</b> , 53, 86-99	36.3	44
150	Inhibition of endothelin-B receptor signaling synergizes with MAPK pathway inhibitors in BRAF mutated melanoma. <i>Oncogene</i> , <b>2021</b> , 40, 1659-1673	9.2	4
149	The State of Melanoma: Emergent Challenges and Opportunities. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 2678-2697	12.9	11
148	Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling. <i>Cancer Discovery</i> , <b>2021</b> , 11, 1716-1735	24.4	6
147	Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma. <i>Oncogene</i> , <b>2021</b> , 40, 5590-5599	9.2	6
146	Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance. <i>Cancer Research</i> , <b>2021</b> , 81, 5230-5241	10.1	1
145	Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. <i>Nature Communications</i> , <b>2021</b> , 12, 5086	17.4	6
144	TRIM15 and CYLD regulate ERK activation via lysine-63-linked polyubiquitination. <i>Nature Cell Biology</i> , <b>2021</b> , 23, 978-991	23.4	3

143	Costimulation of $\mathbb{I}$ CR and TLR7/8 promotes V $\mathbb{I}$ T-cell antitumor activity by modulating mTOR pathway and APC function. <b>2021</b> , 9,		3
142	Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines. <i>Cancer Cell</i> , <b>2020</b> , 38, 829-843.e4	24.3	13
141	SPANX Control of Lamin A/C Modulates Nuclear Architecture and Promotes Melanoma Growth. <i>Molecular Cancer Research</i> , <b>2020</b> , 18, 1560-1573	6.6	3
140	Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2. <i>Cancer Discovery</i> , <b>2020</b> , 10, 1282-1295	24.4	29
139	Pre-clinical modeling of cutaneous melanoma. <i>Nature Communications</i> , <b>2020</b> , 11, 2858	17.4	53
138	Targeting the cyclin-dependent kinase 5 in metastatic melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2020</b> , 117, 8001-8012	11.5	7
137	Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines. <i>Cancer Research</i> , <b>2020</b> , 80, 4314-4323	10.1	25
136	Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma. <i>Molecular Cell</i> , <b>2020</b> , 77, 633-644.e5	17.6	24
135	Nongenetic Mechanisms of Drug Resistance in Melanoma. <i>Annual Review of Cancer Biology</i> , <b>2020</b> , 4, 315-330	13.9	3
134	Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma. <i>Cell Death and Disease</i> , <b>2020</b> , 11, 882	9.8	3
133	Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 6039-6050	12.9	9
132	B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. <i>Nature Communications</i> , <b>2019</b> , 10, 4186	17.4	127
131	A Melanoma Patient-Derived Xenograft Model. <i>Journal of Visualized Experiments</i> , <b>2019</b> ,	1.6	8
130	BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 2783-2794	12.9	18
129	Polyunsaturated Fatty Acids from Astrocytes Activate PPAR $\mathbb{I}$ Signaling in Cancer Cells to Promote Brain Metastasis. <i>Cancer Discovery</i> , <b>2019</b> , 9, 1720-1735	24.4	43
128	Remodeling of the Collagen Matrix in Aging Skin Promotes Melanoma Metastasis and Affects Immune Cell Motility. <i>Cancer Discovery</i> , <b>2019</b> , 9, 64-81	24.4	128
127	Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. <i>EMBO Molecular Medicine</i> , <b>2018</b> , 10,	12	42
126	Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 4771-4784	12.9	21

125	MSX1-Induced Neural Crest-Like Reprogramming Promotes Melanoma Progression. <i>Journal of Investigative Dermatology</i> , <b>2018</b> , 138, 141-149	4.3	20
124	Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. <i>Nature Medicine</i> , <b>2018</b> , 24, 1545-1549	50.5	230
123	Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. <i>Nature</i> , <b>2018</b> , 560, 382-386	50.4	1058
122	Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. <i>Cancer Discovery</i> , <b>2018</b> , 8, 196-215	24.4	228
121	Frontiers in pigment cell and melanoma research. <i>Pigment Cell and Melanoma Research</i> , <b>2018</b> , 31, 728-735	4.5	8
120	A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. <i>Cell</i> , <b>2018</b> , 175, 984-997.e24	56.2	477
119	Recent Advances in Melanoma and Melanocyte Biology. <i>Journal of Investigative Dermatology</i> , <b>2017</b> , 137, 557-560	4.3	10
118	Oncogenic RAS Regulates Long Noncoding RNA in Human Cancer. <i>Cancer Research</i> , <b>2017</b> , 77, 3745-3757	10.1	25
117	Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. <i>Nature</i> , <b>2017</b> , 546, 431-435	50.4	544
116	PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. <i>Nature</i> , <b>2017</b> , 550, 133-136	50.4	100
115	Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. <i>Nature Communications</i> , <b>2017</b> , 8, 607	17.4	80
114	ATG5 Mediates a Positive Feedback Loop between Wnt Signaling and Autophagy in Melanoma. <i>Cancer Research</i> , <b>2017</b> , 77, 5873-5885	10.1	20
113	Enhancing CD8 T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy. <i>Cancer Cell</i> , <b>2017</b> , 32, 377-391.e9	24.3	253
112	Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. <i>Cell Reports</i> , <b>2017</b> , 21, 1936-1952	10.6	45
111	A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. <i>Cell Reports</i> , <b>2017</b> , 21, 1953-1967	10.6	89
110	Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. <i>Oncotarget</i> , <b>2017</b> , 8, 25395-25417	3.3	46
109	Crosstalk in skin: melanocytes, keratinocytes, stem cells, and melanoma. <i>Journal of Cell Communication and Signaling</i> , <b>2016</b> , 10, 191-196	5.2	27
108	Heterogeneity in Melanoma. <i>Cancer Treatment and Research</i> , <b>2016</b> , 167, 1-15	3.5	41

107	Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 1592-602	12.9	91
106	Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. <i>Journal of Clinical Investigation</i> , <b>2016</b> , 126, 1834-56	15.9	167
105	Enhancing the evaluation of PI3K inhibitors through 3D melanoma models. <i>Pigment Cell and Melanoma Research</i> , <b>2016</b> , 29, 317-28	4.5	11
104	The role of Orai-STIM calcium channels in melanocytes and melanoma. <i>Journal of Physiology</i> , <b>2016</b> , 594, 2825-35	3.9	19
103	JARID1B Enables Transit between Distinct States of the Stem-like Cell Population in Oral Cancers. <i>Cancer Research</i> , <b>2016</b> , 76, 5538-49	10.1	28
102	UV-Induced Wnt7a in the Human Skin Microenvironment Specifies the Fate of Neural Crest-Like Cells via Suppression of Notch. <i>Journal of Investigative Dermatology</i> , <b>2015</b> , 135, 1521-1532	4.3	15
101	Melanoma. <i>Nature Reviews Disease Primers</i> , <b>2015</b> , 1, 15003	51.1	283
100	Nivolumab in combination with ipilimumab for the treatment of melanoma. <i>Expert Review of Anticancer Therapy</i> , <b>2015</b> , 15, 1135-41	3.5	16
99	Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells. <i>Pigment Cell and Melanoma Research</i> , <b>2015</b> , 28, 184-95	4.5	61
98	Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulations. <i>Experimental Dermatology</i> , <b>2015</b> , 24, 155-7	4	24
97	Establishing Human Skin Grafts in Mice as Model for Melanoma Progression. <i>Methods in Molecular Biology</i> , <b>2015</b> , 1	1.4	1
96	BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 1652-64	12.9	78
95	Developmental pathways activated in melanocytes and melanoma. <i>Archives of Biochemistry and Biophysics</i> , <b>2014</b> , 563, 13-21	4.1	57
94	EGFR inhibition promotes an aggressive invasion pattern mediated by mesenchymal-like tumor cells within squamous cell carcinomas. <i>Molecular Cancer Therapeutics</i> , <b>2013</b> , 12, 2176-86	6.1	22
93	The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 1784-94	12.9	74
92	Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. <i>Cell Reports</i> , <b>2013</b> , 4, 1090-9	10.6	141
91	Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. <i>Cell Reports</i> , <b>2013</b> , 3, 1252-65	10.6	177
90	Isolation, characterization, and differentiation of human multipotent dermal stem cells. <i>Methods in Molecular Biology</i> , <b>2013</b> , 989, 235-46	1.4	12

89	Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. <i>Cancer Cell</i> , <b>2013</b> , 23, 811-25	24.3	437
88	Therapeutic destruction of insulin receptor substrates for cancer treatment. <i>Cancer Research</i> , <b>2013</b> , 73, 4383-94	10.1	87
87	Comparative secretome analysis of epithelial and mesenchymal subpopulations of head and neck squamous cell carcinoma identifies S100A4 as a potential therapeutic target. <i>Molecular and Cellular Proteomics</i> , <b>2013</b> , 12, 3778-92	7.6	30
86	Combination therapy of immunocytokines with ipilimumab: a cure for melanoma?. <i>Journal of Investigative Dermatology</i> , <b>2013</b> , 133, 595-596	4.3	3
85	Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. <i>Cancer Discovery</i> , <b>2013</b> , 3, 1378-93	24.4	164
84	There is a world beyond protein mutations: the role of non-coding RNAs in melanomagenesis. <i>Experimental Dermatology</i> , <b>2013</b> , 22, 303-6	4	4
83	The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling. <i>PLoS ONE</i> , <b>2013</b> , 8, e59588	3.7	48
82	Isolation and cultivation of dermal stem cells that differentiate into functional epidermal melanocytes. <i>Methods in Molecular Biology</i> , <b>2012</b> , 806, 15-29	1.4	14
81	GSK3 $\beta$ inhibition blocks melanoma cell/host interactions by downregulating N-cadherin expression and decreasing FAK phosphorylation. <i>Journal of Investigative Dermatology</i> , <b>2012</b> , 132, 2818-27	4.3	30
80	Beyond ABC: another mechanism of drug resistance in melanoma side population. <i>Journal of Investigative Dermatology</i> , <b>2012</b> , 132, 2317-2319	4.3	10
79	Targeting CD20 in melanoma patients at high risk of disease recurrence. <i>Molecular Therapy</i> , <b>2012</b> , 20, 1056-62	11.7	54
78	Fibroblasts contribute to melanoma tumor growth and drug resistance. <i>Molecular Pharmaceutics</i> , <b>2011</b> , 8, 2039-49	5.6	90
77	Dermis-derived stem cells: a source of epidermal melanocytes and melanoma?. <i>Pigment Cell and Melanoma Research</i> , <b>2011</b> , 24, 422-9	4.5	49
76	The three-dimensional human skin reconstruct model: a tool to study normal skin and melanoma progression. <i>Journal of Visualized Experiments</i> , <b>2011</b> ,	1.6	54
75	Direct reprogramming of melanocytes to neural crest stem-like cells by one defined factor. <i>Stem Cells</i> , <b>2011</b> , 29, 1752-62	5.8	47
74	A NOTCH3-mediated squamous cell differentiation program limits expansion of EMT-competent cells that express the ZEB transcription factors. <i>Cancer Research</i> , <b>2011</b> , 71, 6836-47	10.1	91
73	Detecting and targeting mesenchymal-like subpopulations within squamous cell carcinomas. <i>Cell Cycle</i> , <b>2011</b> , 10, 2008-16	4.7	37
72	Human dermal stem cells differentiate into functional epidermal melanocytes. <i>Journal of Cell Science</i> , <b>2010</b> , 123, 853-60	5.3	128

71	A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. <i>Cell</i> , <b>2010</b> , 141, 583-94	56.2	874
70	Boris Bastian. <i>Pigment Cell and Melanoma Research</i> , <b>2010</b> , 23, 834	4.5	
69	PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. <i>Pigment Cell and Melanoma Research</i> , <b>2010</b> , 23, 820-7	4.5	122
68	Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. <i>Cancer Cell</i> , <b>2010</b> , 18, 683-95	24.3	1007
67	Embryonic stem cells as a model for studying melanocyte development. <i>Methods in Molecular Biology</i> , <b>2010</b> , 584, 301-16	1.4	3
66	Active Notch1 confers a transformed phenotype to primary human melanocytes. <i>Cancer Research</i> , <b>2009</b> , 69, 5312-20	10.1	93
65	Integrating tumor-initiating cells into the paradigm for melanoma targeted therapy. <i>International Journal of Cancer</i> , <b>2009</b> , 124, 1245-50	7.5	14
64	Driving in the melanoma landscape. <i>Experimental Dermatology</i> , <b>2009</b> , 18, 506-8	4	8
63	The essential role of fibroblasts in esophageal squamous cell carcinoma-induced angiogenesis. <i>Gastroenterology</i> , <b>2008</b> , 134, 1981-93	13.3	96
62	Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 3041-6	11.5	1056
61	In vitro three-dimensional tumor microenvironment models for anticancer drug discovery. <i>Expert Opinion on Drug Discovery</i> , <b>2008</b> , 3, 1-10	6.2	83
60	Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. <i>Cancer Research</i> , <b>2008</b> , 68, 5743-52	10.1	79
59	Melanoma and the tumor microenvironment. <i>Current Oncology Reports</i> , <b>2008</b> , 10, 439-46	6.3	143
58	Matricellular proteins produced by melanocytes and melanomas: in search for functions. <i>Cancer Microenvironment</i> , <b>2008</b> , 1, 93-102	6.1	29
57	Melanoma stem cells: the dark seed of melanoma. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 2890-4	2.2	120
56	Microenvironmental influences in melanoma progression. <i>Journal of Cellular Biochemistry</i> , <b>2007</b> , 101, 862-72	4.7	66
55	Old disease, new culprit: tumor stem cells in cancer. <i>Journal of Cellular Physiology</i> , <b>2007</b> , 213, 603-9	7	33
54	The many faces of Notch signaling in skin-derived cells. <i>Pigment Cell &amp; Melanoma Research</i> , <b>2007</b> , 20, 458-65		49

53	Rewired ERK-JNK signaling pathways in melanoma. <i>Cancer Cell</i> , <b>2007</b> , 11, 447-60	24.3	240
52	Roadmap for new opportunities in melanoma research. <i>Seminars in Oncology</i> , <b>2007</b> , 34, 566-76	5.5	3
51	Role of stem cells in melanoma progression: hopes for a better treatment. <i>Expert Review of Dermatology</i> , <b>2007</b> , 2, 191-201		
50	Targeting BRAF/MEK in melanoma: new hope or another false dawn?. <i>Expert Review of Dermatology</i> , <b>2007</b> , 2, 179-190		
49	Farming cells to rebuild skin and melanoma. <i>Cancer Biology and Therapy</i> , <b>2007</b> , 6, 467-71	4.6	1
48	An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. <i>Cancer Research</i> , <b>2007</b> , 67, 209-17	10.1	207
47	Molecular targets in melanoma: strategies and challenges for diagnosis and therapy. <i>International Journal of Cancer</i> , <b>2006</b> , 118, 523-6	7.5	14
46	Inhibition of endothelial cell proliferation by Notch1 signaling is mediated by repressing MAPK and PI3K/Akt pathways and requires MAML1. <i>FASEB Journal</i> , <b>2006</b> , 20, 1009-11	0.9	93
45	Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. <i>Cancer Research</i> , <b>2006</b> , 66, 4182-90	10.1	228
44	CCN3 controls 3D spatial localization of melanocytes in the human skin through DDR1. <i>Journal of Cell Biology</i> , <b>2006</b> , 175, 563-9	7.3	81
43	Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. <i>Molecular Cancer Therapeutics</i> , <b>2006</b> , 5, 1136-44	6.1	372
42	Isolation of a novel population of multipotent adult stem cells from human hair follicles. <i>American Journal of Pathology</i> , <b>2006</b> , 168, 1879-88	5.8	299
41	Life isn't flat: taking cancer biology to the next dimension. <i>In Vitro Cellular and Developmental Biology - Animal</i> , <b>2006</b> , 42, 242-7	2.6	223
40	Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. <i>Pigment Cell &amp; Melanoma Research</i> , <b>2006</b> , 19, 290-302		378
39	Defining the conditions for the generation of melanocytes from human embryonic stem cells. <i>Stem Cells</i> , <b>2006</b> , 24, 1668-77	5.8	95
38	A tumorigenic subpopulation with stem cell properties in melanomas. <i>Cancer Research</i> , <b>2005</b> , 65, 9328-37	10.1	1047
37	Functional erythropoietin autocrine loop in melanoma. <i>American Journal of Pathology</i> , <b>2005</b> , 166, 823-30	5.8	69
36	Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion. <i>American Journal of Pathology</i> , <b>2005</b> , 166, 1541-54	5.8	122



35	Adhesion, migration and communication in melanocytes and melanoma. <i>Pigment Cell &amp; Melanoma Research</i> , <b>2005</b> , 18, 150-9		251
34	Normal human melanocyte homeostasis as a paradigm for understanding melanoma. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , <b>2005</b> , 10, 153-63	1.1	144
33	Selective evolutionary pressure from the tissue microenvironment drives tumor progression. <i>Seminars in Cancer Biology</i> , <b>2005</b> , 15, 451-9	12.7	48
32	Metastatic melanoma cells. Introduction. <i>Cancer and Metastasis Reviews</i> , <b>2005</b> , 24, 193-4	9.6	5
31	Targeting the stromal fibroblasts: a novel approach to melanoma therapy. <i>Expert Review of Anticancer Therapy</i> , <b>2005</b> , 5, 1069-78	3.5	17
30	Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. <i>Journal of Clinical Investigation</i> , <b>2005</b> , 115, 3166-76	15.9	258
29	The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. <i>Frontiers in Bioscience - Landmark</i> , <b>2005</b> , 10, 2986-3001	2.8	208
28	Induction of melanoma phenotypes in human skin by growth factors and ultraviolet B. <i>Cancer Research</i> , <b>2004</b> , 64, 807-11	10.1	71
27	Truncation of activated leukocyte cell adhesion molecule: a gateway to melanoma metastasis. <i>Journal of Investigative Dermatology</i> , <b>2004</b> , 122, 1293-301	4.3	51
26	The role of altered cell-cell communication in melanoma progression. <i>Journal of Molecular Histology</i> , <b>2004</b> , 35, 309-18	3.3	116
25	Reversal of melanocytic malignancy by keratinocytes is an E-cadherin-mediated process overriding beta-catenin signaling. <i>Experimental Cell Research</i> , <b>2004</b> , 297, 142-51	4.2	29
24	Epidermal growth factor receptor mediates increased cell proliferation, migration, and aggregation in esophageal keratinocytes in vitro and in vivo. <i>Journal of Biological Chemistry</i> , <b>2003</b> , 278, 1824-30	5.4	203
23	Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. <i>Molecular and Cellular Biology</i> , <b>2003</b> , 23, 14-25	4.8	397
22	VEGF-A and alphaVbeta3 integrin synergistically rescue angiogenesis via N-Ras and PI3-K signaling in human microvascular endothelial cells. <i>FASEB Journal</i> , <b>2003</b> , 17, 1931-3	0.9	34
21	Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. <i>Cancer Research</i> , <b>2003</b> , 63, 756-9	10.1	286
20	Melanoma development and progression: a conspiracy between tumor and host. <i>Differentiation</i> , <b>2002</b> , 70, 522-36	3.5	143
19	Fibroblast-dependent differentiation of human microvascular endothelial cells into capillary-like 3-dimensional networks. <i>FASEB Journal</i> , <b>2002</b> , 16, 1316-8	0.9	115
18	Melanoma-stroma interactions: structural and functional aspects. <i>Lancet Oncology</i> , <b>2002</b> , 3, 35-43	21.7	190

17	Osteonectin/SPARC induction by ectopic beta(3) integrin in human radial growth phase primary melanoma cells. <i>Cancer Research</i> , <b>2002</b> , 62, 226-32	10.1	33
16	BRAF and RAS mutations in human lung cancer and melanoma. <i>Cancer Research</i> , <b>2002</b> , 62, 6997-7000	10.1	735
15	Mel-CAM-specific genetic suppressor elements inhibit melanoma growth and invasion through loss of gap junctional communication. <i>Oncogene</i> , <b>2001</b> , 20, 4676-84	9.2	67
14	Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. <i>Oncogene</i> , <b>2001</b> , 20, 8125-35	9.2	160
13	Dynamics of intercellular communication during melanoma development. <i>Trends in Molecular Medicine</i> , <b>2000</b> , 6, 163-9		86
12	Human melanoma progression in skin reconstructs : biological significance of bFGF. <i>American Journal of Pathology</i> , <b>2000</b> , 156, 193-200	5.8	177
11	E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. <i>American Journal of Pathology</i> , <b>2000</b> , 156, 1515-25	5.8	275
10	Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytes. <i>Oncogene</i> , <b>1999</b> , 18, 6469-76	9.2	107
9	Progression-related expression of beta3 integrin in melanomas and nevi. <i>Human Pathology</i> , <b>1999</b> , 30, 562-7	3.7	106
8	Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. <i>American Journal of Pathology</i> , <b>1998</b> , 153, 1435-42	5.8	176
7	Melanoma cell lines from different stages of progression and their biological and molecular analyses. <i>Melanoma Research</i> , <b>1997</b> , 7, S43	3.3	71
6	Interactions of melanocytes and melanoma cells with the microenvironment. <i>Pigment Cell &amp; Melanoma Research</i> , <b>1994</b> , 7, 81-8		34
5	In vitro growth patterns of normal human melanocytes and melanocytes from different stages of melanoma progression. <i>Journal of Immunotherapy</i> , <b>1992</b> , 12, 199-202	5	40
4	Growth and phenotypic characteristics of human nevus cells in culture. <i>Journal of Investigative Dermatology</i> , <b>1988</b> , 90, 134-41	4.3	45
3	Expression of the receptor for epidermal growth factor correlates with increased dosage of chromosome 7 in malignant melanoma. <i>Somatic Cell and Molecular Genetics</i> , <b>1985</b> , 11, 297-302		150
2	Pre-determined diversity in resistant fates emerges from homogenous cells after anti-cancer drug treatment		5
1	Large-scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines		1